Govt intensifies regulatory surveillance against GLP-1 based weight loss drugs

NEW DELHI: Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s unauthorised sale and promotion.

In order to ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance, according to Health Ministry.

Concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics.

These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks.

“Regulatory surveillance will continue to be intensified in the coming weeks and non-compliances will be dealt strictly with actions including cancellation of licenses, penalties, and prosecution under applicable laws,” said the government.